• Home
  • About
  • Portfolio
  • Meet the Team
  • News
  • Contact
  • Investor Portal

  • info@chv.vc

  • 129 South Street, 4th Floor, Boston, MA 02111

Home / News / Sera Prognostics

Sera Prognostics


Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
  • February 15, 2023
  • -
  • Sera Prognostics
Sera Prognostics Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the PRETRM® Test-and-Treat Strategy Across Diverse Populations
  • November 15, 2022
  • -
  • Sera Prognostics
Banner Health, Sera Prognosics Team Up to Provide PreTRM® Test to Cover Pregnant Members
  • September 22, 2022
  • -
  • Sera Prognostics
Sera Prognostics Presents Data Demonstrating the Health & Economic Benefit of PRETRM® Testing at Ispor Annual Meeting
  • May 20, 2022
  • -
  • Sera Prognostics
Sera Prognostics and Newborn Foundation Partner to Reduce Risks Associated with Preterm Birth and Improve Health Equity Through the “Every Mother, Every Baby” Project
  • May 5, 2022
  • -
  • Sera Prognostics
Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting
  • March 18, 2022
  • -
  • Sera Prognostics
Sera Prognostics Added to NASDAQ Biotechnology Index
  • December 17, 2021
  • -
  • Sera Prognostics
Sera Prognostics Announces Collaboration to Help Underserved Communities Make Informed Decision about Prenatal Health
  • November 4, 2021
  • -
  • Sera Prognostics
Show More

Let’s Connect.

Contact Us
https://chv.vc/wp-content/uploads/2020/08/footer-logo.png

Sitemap

  • Home
  • About
  • Portfolio
  • Meet the Team
  • News
  • Contact
  • Investor Portal

About

Catalyst Health Ventures (CHV) is a venture capital fund investing in transformative medical technologies addressing global unmet needs.

Contact

  • info@chv.vc

Boston Web Design by GoingClear